Jon Ellis
Director/Board Member chez Orchard Therapeutics (Europe) Ltd.
Profil
Actuellement, Jon Ellis occupe le poste de vice-président et responsable de la science et de la technologie chez GlaxoSmithKline Plc. Il est également membre du conseil d'administration d'Orchard Therapeutics (Europe) Ltd. et d'Orchard Therapeutics Plc. Le Dr Ellis a obtenu un doctorat de l'université de Cambridge, un MBA du Henley Management College et un diplôme de premier cycle et un diplôme d'études supérieures du Magdalene College.
Postes actifs de Jon Ellis
Sociétés | Poste | Début |
---|---|---|
Orchard Therapeutics (Europe) Ltd.
Orchard Therapeutics (Europe) Ltd. BiotechnologyHealth Technology Orchard Therapeutics (Europe) Ltd. researches on transformative gene therapies. Its services include stem cell technology, gene therapy, eradicating orphan diseases, and paediatric diseases. The company was founded by Andrea Spezzi and Nicolas Koebel on September 1, 2015 and is headquartered in London, the United Kingdom. | Director/Board Member | 02/08/2018 |
Anciens postes connus de Jon Ellis
Sociétés | Poste | Fin |
---|---|---|
GSK PLC | Chief Tech/Sci/R&D Officer | 01/08/2022 |
ORCHARD THERAPEUTICS PLC | Director/Board Member | 16/06/2021 |
Formation de Jon Ellis
University of Cambridge | Doctorate Degree |
Henley Management College | Masters Business Admin |
Magdalene College | Graduate Degree |
Expériences
Fonctions occupées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
Sociétés cotées | 1 |
---|---|
GSK PLC | Health Technology |
Entreprise privées | 2 |
---|---|
Orchard Therapeutics (Europe) Ltd.
Orchard Therapeutics (Europe) Ltd. BiotechnologyHealth Technology Orchard Therapeutics (Europe) Ltd. researches on transformative gene therapies. Its services include stem cell technology, gene therapy, eradicating orphan diseases, and paediatric diseases. The company was founded by Andrea Spezzi and Nicolas Koebel on September 1, 2015 and is headquartered in London, the United Kingdom. | Health Technology |
Orchard Therapeutics Plc
Orchard Therapeutics Plc Pharmaceuticals: MajorHealth Technology Orchard Therapeutics Plc is a biopharmaceutical company, which engages in discovering, acquiring, developing and commercializing gene therapies for patients with rare disorders. The company focuses on its autologous ex vivo gene therapy approach on three therapeutic rare disease franchise areas: primary immune deficiencies, neurometabolic disorders, and hemoglobinopathies. Its portfolio includes Strimvelis, a commercial-stage gamma retroviral-based product for the treatment of Adenosine deaminase deficiency (ADA-SCID). The company was founded by Nicolas Koebel and Andrea Spezzi in August 2018 and is headquartered in London, the United Kingdom. | Health Technology |